The overexpression of miR-622 in BRCA1-mutant breast and ovarian cancer cell lines MDA-MB436 and UWB1.289 induced resistance to the PARPis olaparib and veliparib as well as to platinum chemotherapy [58]. Here, BRCA1 is linked to ovarian carcinoma.